ERBB3 and ovarian carcinoma: Overexpression of HER3 has been implicated in the progression of ovarian cancer and in the development of chemotherapy resistance, as it can compensate for or reactivate survival pathways when tumors are challenged with targeted therapies or cytotoxic drugs [25,28].